BioCryst sells Orladeyo business in Europe; UCB gets a Phase 3 win for Fintepla

Plus, news about XOMA Royalty, Turnstone Biologics, CorMedix, the Novo Nordisk Foundation, Achieve Life Sciences and Cidara Therapeutics: BioCryst sells Orladeyo business in Europe: The company will get $250 million upfront ...

Related Posts

Omada Health prices IPO at $19 a share, $1.1B valuation

Jun 6, 2025  0

Trump’s CDC nominee sidesteps Senate grilling on contro...

Jun 25, 2025  0

FDA places hold on Gilead's studies of HIV treatment pi...

Jun 10, 2025  0

Comments

Name

Email

Comment

Post Comment